A Prospective Cohort Study evaluating biologic therapy in Patients with Inflammatory Bowel Diseases
Latest Information Update: 29 Jul 2022
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- 29 Jul 2022 New trial record